u/dilara_weiss

Which programme and which readout are you quoting?

phase 3 is where the comparison becomes fair

Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.

Yes — the consultation that asks nothing tells you what kind of service it is.

Disagreeing with this line: that is the arrangement in one nation and the question is about another.

Correction: that supplier is in the documented twenty with a source page, not in the wider-market table.

sofia_nascimento is describing the batch record test and it is the fastest signal available before you spend anything.

consistency across lots beats one spectacular result

the Irish scheme cap is the single most useful fact in this board

Adding the practical bit — ask what happens at discharge before you start, not after.

daily dosing, not weekly, so the exposure profile is different

Correction: that supplier is in the documented twenty with a source page, not in the wider-market table. Different evidence bases entirely.

Fixing my own comment above: I said 14 orders and it is 19. The pattern is the same, the count was wrong.

Independent testing is worth more than a supplied certificate for one structural reason: the chain of custody. A member who buys, ships and pays is testing the same thing you would receive.

Sent the same compound from TFC and GL Biochem to Janoshik in the same month. Both came back above the claim on the certificate — mine was 98.1% on a stated 97.5%.

That is a report count, not a test count. The table lists both and they are very different numbers.

Agreed on buying small first. The cost of a test is small next to the cost of committing to a supplier you have not checked.

Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.

This is the fact the whole board hangs on. Small molecule, not peptide.

Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.

Cosigning on lot matching. It sounds trivial and it predicts almost everything else about how an operation is run.

Sent the same compound from TFC and Homopeptide to VendorInvestigate in the same month. Both came back above the claim on the certificate — mine was 98.6% on a stated 98.5%.

The two routes, described separately, because mixing them is where most of the confusion here starts.

lane_watcher is right that the two routes are separate. A private prescription does not move you up the list.

Yes, and the reason the wider-market table has no scores is that a score built on two reports would be a lie with a decimal point.

NHS pathway or private prescription?

A certificate with a purity figure and no method line is not falsifiable. You cannot reproduce it, you cannot check it, and it tells you nothing about how the number was produced.

What did the tolerability table look like at that dose?

I would not read a supply notice as a shortage in your pharmacy tomorrow. They are not the same thing.

It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.

the boards keep comparing it to injectables at matched doses, which is meaningless

A private prescription is an independent route: it does not affect NHS list position, and it is not a step in the same pathway.

Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.

Asked CPC for the batch record on a Tuesday and had the full document, batch and method line, before the end of the day. That is the bar now.

Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.

The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.

That is a phase 2 result being quoted as though the programme had reported.

Pharmacy pricing on a private prescription is set by the pharmacy. The spread between them in a given month is routinely substantial, which is why a tracker built from member reports is more useful than any headline.

do not assume reconstitution intuitions apply, there is nothing to reconstitute

the lot on the vial has to match the lot on the certificate, every time

Which pharmacy, and what did they quote for the month rather than the first month?

Correction: that threshold is your ICB’s, not a national one. They differ and they change by year.

How many separate lots is that across?

Adding the practical version: ask for lead time, minimum quantity and the batch record in the same message. Three answers, one email.